Purple Biotech Ltd. (PPBT) Company Overview

What does Purple Biotech do?

Purple Biotech Ltd. is an Israeli clinical-stage oncology company listed on Nasdaq and the Tel Aviv Stock Exchange under PPBT. It does not currently sell an approved drug or generate product revenue. Its economic value therefore rests on whether a small pipeline of experimental cancer therapies can produce convincing clinical evidence, attract a partner, and eventually reach regulatory approval. The company describes its mission as developing first-in-class therapies that use the tumor microenvironment to overcome drug resistance, a focus reflected in its official company overview.

Which assets define the company?

This is a very different model from a diversified pharmaceutical company. Purple is closer to a portfolio of scientific options financed by repeated capital raises. The central analytical question is not current market share or revenue growth; it is whether preclinical and clinical milestones increase the probability-adjusted value of the pipeline faster than cash is consumed and shareholders are diluted.

How does Purple Biotech make money?

Purple Biotech currently has no recurring commercial revenue stream. Its filings state that its oncology candidates are still in research and development and that operations have historically been financed mainly through equity offerings. In practical terms, the company spends cash on laboratory work, manufacturing development, toxicology, regulatory preparation, and clinical trials; value is created only if those expenditures produce data that can support licensing, partnership, acquisition, or eventual commercialization.

What is the likely monetization path?

Why has CAPTN-3 become the core value driver?

In its first-quarter 2026 update, management said resources had been redirected toward CAPTN-3, with IM1240 the lead development priority and IM1305 supporting the broader platform opportunity. CM24 and NT219 remain potential partnering assets, but Purple no longer appears willing to fund their next steps alone. That shift concentrates scarce cash on one platform that management believes can offer both efficacy and safety advantages.

What does the latest quarter show?

The quarter ended March 31, 2026 showed a company increasing investment in CAPTN-3 while still operating with a small cash cushion. Research and development expense rose because of chemistry, manufacturing, and controls work, while general and administrative costs also increased. The reported IFRS net loss was unusually low because non-cash warrant remeasurement generated finance income; the adjusted loss better represents the underlying operating burn.

Why does the adjusted loss matter more than the IFRS loss?

Warrants are remeasured through finance income or expense. A favorable fair-value movement can make the net loss look small without adding operating cash. Students and investors should therefore separate accounting volatility from the cash cost of advancing the pipeline. The $2.1 million adjusted operating loss is much closer to the economic spending rate than the $0.1 million IFRS net loss. The roughly $3.1 million decline in cash and deposits from year-end to quarter-end also shows why financing capacity remains central.

How did strategic turning points shape Purple Biotech?

Purple’s current structure is the result of several acquisitions, clinical readouts, financing events, and a 2025-2026 portfolio reset. The history matters because each acquired program brought intellectual property and scientific optionality, but also added development obligations that a micro-cap balance sheet could not fund indefinitely.

1. 2017
   Purple acquired control of TyrNovo, bringing NT219 and its IRS1/2-STAT3 resistance biology into the portfolio.
2. 2020
   The FameWave transaction added CM24, shifting the company further toward immuno-oncology combinations.
3. 2023
   Acquisition of Immunorizon introduced the CAPTN-3 tri-specific platform and ultimately changed the company’s strategic center of gravity.
4. 2024
   CM24 Phase 2 work concluded, reducing trial expense and allowing management to compare mature clinical assets with the newer platform.
5. 2025
   IM1240 achieved manufacturing and scalability progress; Purple also raised $6.0M gross in a September public offering.
6. 2025 year-end
   The company impaired $20.5M of in-process R&D tied to CM24 and NT219, signaling lower internal commitment to those assets.
7. 2026
   CAPTN-3 became the explicit core priority, supported by new patient-derived data, a scientific advisory board, and a computational-design collaboration.

What did the 2025 impairment really signal?

The impairment was non-cash, but it was strategically meaningful. Purple’s 2025 Form 20-F recorded a $20.5 million write-down of in-process R&D associated with CM24 and NT219. The accounting does not prove those molecules have no scientific value; it says the expected recoverable value under the company’s funding and development assumptions had fallen. That is consistent with a strategy of seeking external investment or partners rather than continuing expensive internal trials.

What gives CAPTN-3 a potential competitive advantage?

Purple’s proposed differentiation is a tri-specific architecture that combines tumor targeting, T-cell engagement, and NK-cell checkpoint blockade. IM1240 binds 5T4 on tumor cells, CD3 on T cells, and NKG2A on NK and some T cells. The CD3 arm is masked with a cleavable cap intended to reduce peripheral immune activation and become more active in the tumor environment. This design attempts to solve a familiar immuno-oncology problem: powerful immune engagement can produce anti-tumor activity, but off-tumor activation can narrow the therapeutic window.

What evidence supports the design?

The annual report describes picomolar cytotoxicity against 5T4-positive cancer cells, dose-dependent activity, and dependence on both the CD3 and NKG2A arms in patient-derived models. It also reports analysis of approximately 26,000 human transcriptomes supporting co-expression of NKG2A, HLA-E, and 5T4 in solid tissues rather than blood. In non-human primate work, management said cytokine release remained modest at doses up to 300-fold higher than a non-capped comparator. New data filed in June 2026 emphasized favorable safety, pharmacokinetics, and a broad therapeutic window in preclinical testing; the related June 2026 Form 6-K identifies the EACR presentation.

Why is this not yet a moat?

A platform becomes defensible only when patents, manufacturability, translational evidence, and human clinical data reinforce each other. Purple has disclosed a commercially viable manufacturing yield for IM1240 and a differentiated mechanistic hypothesis, but it has not yet shown safety or efficacy in patients. Competitors are developing 5T4-targeted antibody-drug conjugates, bispecifics, T-cell engagers, and conditionally activated biologics. The moat is therefore prospective: a design advantage must survive first-in-human testing before it can create bargaining power.

Who are Purple Biotech’s main competitors?

Purple competes in several overlapping markets rather than one neat category. IM1240 faces companies developing 5T4-targeted therapies, masked T-cell engagers, NK-cell checkpoint approaches, and multispecific antibodies. CM24 competes with other strategies targeting immune suppression in pancreatic cancer, while NT219 competes with therapies aimed at bypassing resistance to EGFR inhibitors and immune checkpoint drugs.

What determines market position for a pre-revenue biotech?

Market position is measured by evidence rather than sales. The most important factors are novelty of mechanism, reproducibility across models, safety margin, manufacturability, patent life, regulatory clarity, and partner interest. Purple’s official pipeline page shows a focused portfolio, but focus creates concentration. A single disappointing toxicology result, manufacturing delay, or weak early clinical signal could materially change competitive standing.

How financially strong is Purple Biotech?

Purple has no operating revenue, a long history of losses, and a capital structure shaped by ADS offerings, warrants, and periodic dilution. At December 31, 2025, it had $9.5 million of cash and deposits; by March 31, 2026, that figure had declined to $6.4 million. Management estimated runway into 2027, but a first-in-human program can require additional manufacturing, regulatory, and clinical spending beyond the currently funded milestones.

How should dilution be interpreted?

In September 2025, Purple raised $6.0 million gross through 600,000 ADSs or pre-funded warrants plus short-term warrants for up to 1.2 million ADSs. Earlier financings included $2.8 million gross in December 2024 and $2.0 million from warrant exercises in July 2024. These transactions kept development alive but expanded the potential share count. For valuation, the relevant denominator is not just current ADSs outstanding; analysts must consider pre-funded warrants, ordinary warrants, employee awards, the ADS ratio, and future capital needs.

Who owns Purple Biotech stock, and why does governance matter?

Purple has one class of ordinary shares with equal voting rights, and each ADS represents 2,000 ordinary shares. The 2025 annual report says no shareholder has different voting rights and the company is not controlled by another corporation or government. Ownership is therefore dispersed in formal voting terms, but financing investors and warrant holders can still have meaningful economic influence.

What does the ADS structure change?

The Bank of New York Mellon is the depositary for the ADR program. At March 18, 2026, BNY held about 84% of outstanding ordinary shares in custody, largely for ADS holders and nominees. This does not mean BNY economically owns the business. It means voting and settlement pass through the depositary structure. The company’s annual ownership disclosures are therefore more informative than a simple record-holder list.

Which KPIs matter most for Purple Biotech?

Traditional revenue and margin metrics are secondary until a product is approved. The most useful KPIs are scientific milestones, cash runway, spending efficiency, financing capacity, and partnerability. These metrics connect biology to valuation.

What should researchers monitor next?

What opportunities could change the story?

The largest opportunity is that CAPTN-3 proves to be a reusable platform rather than a single molecule. If IM1240 demonstrates that masked CD3 engagement plus NKG2A blockade can improve the therapeutic window, Purple could generate additional candidates against other tumor antigens. IM1305, which targets TROP2, is an early example of platform expansion. The company also formed a scientific advisory board and expanded a collaboration with Converge Bio to support design and optimization of new tri-specific antibodies.

Could CM24 still matter?

CM24 produced final randomized Phase 2 pancreatic-cancer data that management described as showing improved outcomes across efficacy endpoints and a stronger signal in an APC-loss biomarker subgroup. The official CM24 publication archive provides the scientific context. A biomarker-enriched development path could be attractive to a partner if the signal is reproducible and the trial design is feasible. However, partnership terms would reflect the need for additional confirmatory development.

Could NT219 create optionality?

NT219’s dual inhibition of IRS1/2 and STAT3 gives it a differentiated resistance-focused rationale. Purple has studied it with cetuximab and pembrolizumab in recurrent or metastatic head-and-neck cancer, as described on the official NT219 page. The opportunity is not near-term product revenue; it is a partner deciding that the mechanism complements an existing oncology franchise.

What risks could weaken Purple Biotech’s outlook?

Purple’s risks are unusually concentrated because the company is small, pre-revenue, and dependent on external financing. The 2025 annual report states that it has a history of operating losses, expects further substantial losses, and may never become profitable. It also had an accumulated deficit of $171 million at December 31, 2025.

Which risk is most immediate?

Financing risk is immediate because the company’s March 2026 cash balance was only a few quarters of the Q1 adjusted operating-loss rate, before considering any step-up in clinical spending. Management’s runway estimate extends into 2027, but the timing and size of the next financing may depend on market conditions and milestone progress. Raising capital after weak data could be highly dilutive.

Which scientific risks matter most?

• Translation risk: activity in cell systems, mice, patient-derived explants, and non-human primates may not predict efficacy or tolerability in humans.
• Safety risk: T-cell engagers can cause cytokine release and other immune toxicities; masking may not be complete or sufficiently tumor-selective.
• Manufacturing risk: tri-specific antibodies are complex biologics, and process changes can affect yield, stability, and comparability.
• Regulatory risk: authorities may request additional toxicology, CMC work, or trial safeguards before or during clinical development.
• Concentration risk: the strategic pivot makes CAPTN-3 the main internal value driver.
• Partner risk: CM24 and NT219 may not secure acceptable terms, leaving prior investment stranded.

Why does Purple Biotech matter for valuation?

A conventional DCF based on current revenue is not useful because there is no commercial revenue base to forecast. Purple is better analyzed through a risk-adjusted net present value framework: estimate the potential economics of each program, multiply by the probability of technical and regulatory success, discount for time, subtract future development costs, add cash, and then divide by a fully diluted share count.

What is the key modeling tension?

Scientific progress can increase enterprise value while financing reduces value per share. A model that ignores future dilution will overstate upside; a model that ignores platform optionality may understate it. The most defensible approach is to use separate scenarios for IM1240, platform extensions, CM24, and NT219, with conservative probabilities and explicit financing assumptions. The company’s March 2026 corporate presentation is useful for mapping management’s milestone sequence, but a valuation should haircut timelines and account for execution risk.

What is the key takeaway from Purple Biotech analysis?

Purple Biotech is a focused, high-risk oncology development company whose future now depends primarily on CAPTN-3 and its lead tri-specific antibody, IM1240. The strategic case is that combining tumor targeting, masked T-cell engagement, and NK-cell checkpoint blockade could create a broader therapeutic window than conventional immune engagers. Preclinical results, manufacturing progress, and patient-derived models provide a coherent scientific rationale, but human proof is still absent.

For students, Purple is a useful case study in biotechnology strategy: management must decide when to stop funding older assets, concentrate capital on a new platform, and seek partners before internal cash is exhausted. For researchers, the decisive questions are whether IM1240’s masking and NKG2A components add measurable benefit in humans. For investors, the next milestones should be judged against cash consumption and fully diluted ownership, not only against headline scientific claims.

The practical watch list is clear: IND-enabling completion, first-in-human timing, early safety and pharmacokinetic data, evidence of anti-tumor activity, a CM24 or NT219 partnership, quarterly adjusted operating loss, quarter-end cash, and the terms of any new financing. Positive clinical translation could materially increase strategic value; delays or toxicity could force another reset. Purple therefore matters less as a traditional earnings story and more as a tightly financed experiment in whether differentiated immuno-oncology engineering can be converted into partnerable clinical evidence.